XML 28 R7.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended March 31,
Dollars in millions20252024
Net product sales$10,886 $11,559 
Alliance revenues88 134 
Other revenues
227 172 
Total Revenues$11,201 $11,865 

The following table summarizes GTN adjustments:
Three Months Ended March 31,
Dollars in millions20252024
Gross product sales$19,874 $19,295 
GTN adjustments(a)
Charge-backs and cash discounts(2,958)(2,556)
Medicaid and Medicare rebates(3,840)(3,084)
Other rebates, returns, discounts and adjustments(2,190)(2,096)
Total GTN adjustments(b)
(8,988)(7,736)
Net product sales$10,886 $11,559 
(a)    Includes reductions to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $289 million and $80 million for the three months ended March 31, 2025 and 2024, respectively.
(b)    Includes U.S. GTN adjustments of $8.2 billion and $6.9 billion for the three months ended March 31, 2025 and 2024, respectively.
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended March 31,
Dollars in millions20252024
Growth Portfolio
Opdivo$2,265 $2,078 
Opdivo Qvantig
9 — 
Orencia770 798 
Yervoy624 583 
Reblozyl478 354 
Opdualag252 206 
Breyanzi263 107 
Camzyos
159 84 
Zeposia107 110 
Abecma
103 82 
Sotyktu55 44 
Krazati
48 21 
Cobenfy
27 — 
Other Growth products(a)
403 325 
Total Growth Portfolio
5,563 4,792 
Legacy Portfolio
Eliquis3,565 3,720 
Revlimid936 1,669 
Pomalyst/Imnovid658 865 
Sprycel175 374 
Abraxane105 217 
Other Legacy products(b)
199 228 
Total Legacy Portfolio
5,638 7,073 
Total Revenues$11,201 $11,865 
United States$7,873 $8,476 
International(c)
3,110 3,190 
Other(d)
218 199 
Total Revenues$11,201 $11,865 
(a)    Includes Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)     Includes Puerto Rico.    
(d)    Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $444 million and $182 million for the three months ended March 31, 2025 and 2024, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.